Work

Orelabrutinib plus bendamustine-rituximab (OBR) Versus Bendamustine-rituximab (BR) in transplant-ineligible, intermediate- to high-risk Mantle Cell Lymphoma (MCL)

Year: 2025

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2025-3599

Authors: Li Wang, Jianzhen Shen, Yaohui Huang, Jing Bao, Lin Shen, Pengpeng Xu, Shu Cheng, Hongming Zhu, Weili Zhao

Institutions: Shanghai Jiao Tong University, Ruijin Hospital, Fujian Medical University, Union Hospital, Anhui Medical University, First Affiliated Hospital of Anhui Medical University, Fudan University

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4417009126

Cites:

Cited by:

Related to: